Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?

New England Journal of Medicine

Volumn 344, Issue 7, 2001, Pages 520-522

  Frenkel, L M ^a   Mullins, J I ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; DRUG SENSITIVITY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIREMIA;

EID: 0035864854     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200102153440710     Document Type: Editorial

References (13)

1. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
2. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
3. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
4. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
5. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
6. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
7. Altered viral fitness of HIV-1 following failure of protease inhihitor-based therapy
8. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
9. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy
10. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
11. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
12. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
13. HIV genotype and phenotype - Arresting resistance?